Vertex Expands Patents Fight with Lupin on Cystic Fibrosis Drug

Vertex Pharmaceuticals Inc. expanded its courtroom fight to protect Kalydeco, alleging that a generic version proposed by Lupin Ltd. infringes four patents for the cystic fibrosis treatment, according to a federal lawsuit in Delaware.

One patent, which expires in February 2033, was added April 14 to the listing for Kalydeco’s granule formulations in the US Food and Drug Administration’s registry of approved drugs, known as the Orange Book, according to a complaint filed July 22 in the US District Court for the District of Delaware.

Two of the case’s other patents also expire in February 2033, the suit says. ...